|
1
|
Zhang W, Yan Y, Gu M, Wang X, Zhu H, Zhang
S and Wang W: High expression levels of Wnt5a and Ror2 in laryngeal
squamous cell carcinoma are associated with poor prognosis. Oncol
Lett. 14:2232–2238. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Riga M, Chelis L, Danielides V, Vogiatzaki
T, Pantazis TL and Pantazis D: Systematic review on T3 laryngeal
squamous cell carcinoma; still far from a consensus on the optimal
organ preserving treatment. Eur J Surg Oncol. 43:20–31. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shen Z, Cao B, Lin L, Zhou C, Ye D, Qiu S,
Li Q and Cui X: The clinical signification of claudin-11 promoter
hypermethylation for laryngeal squamous cell carcinoma. Med Sci
Monit. 23:3635–3640. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mao Y, Zhang DW, Lin H, Xiong L, Liu Y, Li
QD, Ma J, Cao Q, Chen RJ, Zhu J and Feng ZQ: Alpha B-crystallin is
a new prognostic marker for laryngeal squamous cell carcinoma. J
Exp Clin Cancer Res. 31:1012012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Evan GI and Vousden KH: Proliferation,
cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Radogna F, Dicato M and Diederich M:
Cancer-type-specific crosstalk between autophagy, necroptosis and
apoptosis as a pharmacological target. Biochem Pharmacol. 94:1–11.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sousa GFD, Wlodarczyk SR and Monteiro G:
Carboplatin: Molecular mechanisms of action associated with
chemoresistance. Braz J Pharm Sci. 50:693–701. 2014. View Article : Google Scholar
|
|
9
|
Castrellon AB, Pidhorecky I, Valero V and
Raez LE: The role of carboplatin in the neoadjuvant chemotherapy
treatment of triple negative breast cancer. Oncol Rev. 11:3242017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Johnstone TC, Park GY and Lippard SJ:
Understanding and improving platinum anticancer
drugs-phenanthriplatin. Anticancer Res. 34:471–476. 2014.PubMed/NCBI
|
|
11
|
Fong CW: Platinum based
radiochemotherapies: Free radical mechanisms and radiotherapy
sensitizers. Free Radic Biol Med. 99:99–109. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee CK, Jung M, Choi HJ, Kim HR, Kim HS,
Roh MR2, Ahn JB, Chung HC, Heo SJ, Rha SY and Shin SJ: Results of a
phase II study to evaluate the efficacy of docetaxel and
carboplatin in metastatic malignant melanoma patients who failed
first-line therapy containing dacarbazine. Cancer Res Treat.
47:781–789. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sanborn RE: Cisplatin versus carboplatin
in NSCLC: Is there one ‘best’ answer? Curr Treat Option On.
9:326–342. 2008. View Article : Google Scholar
|
|
14
|
Comella P, Gambardella A, Frasci G,
Avallone A and Costanzo R: SICOG investigators: Comparison of the
safety and efficacy of paclitaxel plus gemcitabine combination in
young and elderly patients with locally advanced or metastatic
non-small cell lung cancer. A retrospective analysis of the
Southern Italy Cooperative Oncology Group trials. Crit Rev Oncol
Hematol. 65:164–171. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Barghout SH, Zepeda N, Vincent K, Azad AK,
Xu Z, Yang C, Steed H, Postovit LM and Fu YX: RUNX3 contributes to
carboplatin resistance in epithelial ovarian cancer cells. Gynecol
Oncol. 138:647–655. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lum E, Vigliotti M, Banerjee N, Cutter N,
Wrzeszczynski KO, Khan S, Kamalakaran S, Levine DA, Dimitrova N and
Lucito R: Loss of DOK2 induces carboplatin resistance in ovarian
cancer via suppression of apoptosis. Gynecol Oncol. 130:369–376.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
de Castria TB, da Silva EM, Gois AF and
Riera R: Cisplatin versus carboplatin in combination with
third-generation drugs for advanced non-small cell lung cancer.
Cochrane Db Syst Rev. 8:CD0092562013.
|
|
18
|
Zhang Q, Cheng Y, Huang L, Bai Y, Liang J
and Li X: Inhibitory effect of carboplatin in combination with
bevacizumab on human retinoblastoma in an in vitro and in vivo
model. Oncol Lett. 14:5326–5332. 2017.PubMed/NCBI
|
|
19
|
Montero AJ and Jassem J: Cellular redox
pathways as a therapeutic target in the treatment of cancer. Drugs.
71:1385–1396. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fulda S and Debatin KM: Extrinsic versus
intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene.
25:4798–4811. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Green DR: Apoptotic pathways: Paper wraps
stone blunts scissors. Cell. 102:1–4. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kelland L: The resurgence of
platinum-based cancer chemotherapy. Nat Rev Cancer. 7:573–584.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nicolson MC, Orr RM, O'Neill CF and Harrap
KR: The role of platinum uptake and glutathione levels in L1210
cells sensitive and resistant to cisplatin, tetraplatin or
carboplatin. Neoplasma. 39:189–195. 1992.PubMed/NCBI
|
|
24
|
He P, Ahn JC, Shin JI, Hwang HJ, Kang JW,
Lee SJ and Chung PS: Enhanced apoptotic effect of combined modality
of 9-hydroxypheophorbide alpha-mediated photodynamic therapy and
carboplatin on AMC-HN-3 human head and neck cancer cells. Oncol
Rep. 21:329–334. 2009.PubMed/NCBI
|
|
25
|
He P, Bo S, Chung PS, Ahn JC and Zhou L:
Photosensitizer effect of 9-hydroxypheophorbide α on diode
laser-irradiated laryngeal cancer cells: Oxidative stress-directed
cell death and migration suppression. Oncol Lett. 12:1889–1895.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Evtodienko YuV, Teplova V, Khawaja J and
Saris NE: The Ca(2+)-induced permeability transition pore is
involved in Ca(2+)-induced mitochondrial oscillations: A study on
permeabilised Ehrlich ascites tumour cells. Cell Calcium.
15:143–152. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hunter DR and Haworth RA: The Ca2+-induced
membrane transition in mitochondria. I. The protective mechanisms.
Arch Biochem Biophys. 195:453–459. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Giorgi C, Romagnoli A, Pinton P and
Rizzuto R: Ca2+ signaling, mitochondria and cell death. Curr Mol
Med. 8:119–130. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hong SJ, Dawson TM and Dawson VL: Nuclear
and mitochondrial conversations in cell death: PARP-1 and AIF
signaling. Trends Pharmacol Sci. 25:259–264. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gonzalez D, Bejarano I, Barriga C,
Rodriguez AB and Pariente JA: Oxidative stress-induced caspases are
regulated in human myeloid HL-60 cells by calcium signal. Curr
Signal Transduct Ther. 5:181–186. 2010. View Article : Google Scholar
|
|
31
|
Wajant H: The Fas signaling pathway: More
than a paradigm. Science. 296:1635–1636. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Su SH, Su SJ, Lin SR and Chang KL:
Cardiotoxin-III selectively enhances activation-induced apoptosis
of human CD8+ T lymphocytes. Toxicol Appl Pharmacol. 193:97–105.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hah SS, Stivers KM, de Vere White RW and
Henderson PT: Kinetics of carboplatin-DNA binding in genomic DNA
and bladder cancer cells as determined by accelerator mass
spectrometry. Chem Res Toxicol. 19:622–626. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cheng CF, Juan SH, Chen JJ, Chao YC, Chen
HH, Lian WS, Lu CY, Chang CI, Chiu TH and Lin H: Pravastatin
attenuates carboplatin-induced cardiotoxicity via inhibition of
oxidative stress associated apoptosis. Apoptosis. 13:883–894. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hwang H, Biswas R, Chung PS and Ahn JC:
Modulation of EGFR and ROS induced cytochrome c release by
combination of photodynamic therapy and carboplatin in human
cultured head and neck cancer cells and tumor xenograft in nude
mice. J Photochem Photobiol B. 128:70–77. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gunter TE and Pfeiffer DR: Mechanisms by
which mitochondria transport calcium. Am J Physiol. 258:C755–C786.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Joza N, Susin SA, Daugas E, Stanford WL,
Cho SK, Li CY, Sasaki T, Elia AJ, Cheng HY, Ravagnan L, et al:
Essential role of the mitochondrial apoptosis-inducing factor in
programmed cell death. Nature. 410:549–554. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zamzami N, Marchetti P, Castedo M,
Decaudin D, Macho A, Hirsch T, Susin SA, Petit PX, Mignotte B and
Kroemer G: Sequential reduction of mitochondrial transmembrane
potential and generation of reactive oxygen species in early
programmed cell death. J Exp Med. 182:367–377. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Boya P, Morales MC, Gonzalez-Polo RA,
Andreau K, Gourdier I, Perfettini JL, Larochette N, Deniaud A,
Baran-Marszak F, Fagard R, et al: The chemopreventive agent
N-(4-hydroxyphenyl)retinamide induces apoptosis through a
mitochondrial pathway regulated by proteins from the Bcl-2 family.
Oncogene. 22:6220–6230. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Richter C and Kass GE: Oxidative stress in
mitochondria: Its relationship to cellular Ca2+ homeostasis, cell
death, proliferation, and differentiation. Chem Biol Interact.
77:1–23. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Los G, Smals OA, van Vugt MJ, van der
Vlist M, den Engelse L, McVie JG and Pinedo HM: A rationale for
carboplatin treatment and abdominal hyperthermia in cancers
restricted to the peritoneal cavity. Cancer Res. 52:1252–1258.
1992.PubMed/NCBI
|
